Posters

"Pooled data analysis of the safety and tolerability of intravenous Pelareorep in combination with chemotherapy in 500 + cancer patients." Gutierrez et al, ESMO September 2017

Learn More

"Mechanism of Pelareorep (Pel)-mediated cell death in a Phase I study in combination with irinotecan/ fluorouracil/ leucovorin/ bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC)." Goel et al, ESMO September 2017

Learn More

"A randomized (RCT) phase II study of oncolytic reovirus (pelareorep) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC)." Bernstein et al, ASCR April 2017

Learn More

"Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN® in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma." Mahalingam et al, EMSO July 2015

Learn More

"PDL-1 blockade and Sunitinib enhance the efficiency of oncolytic viral therapy." Mostafa et al

Learn More

"Combination therapy with reovirus and PD-1 blockade effectively establishes tumor control via innate and adaptive immune responses." Rajani et al

Learn More

"Combination therapy with reovirus and immunomodulatory drugs induces direct oncolytic and immune-mediated killing of multiple myeloma cells and overcomes stromal-mediated microenvironmental protection." Parrish et al, ASH 2014

Learn More

Presentations

"Renaissance of Reovirus as a True Immuno-Oncology Viral Agent for Cancer." Dr. Andres Gutierrez, Immuno-Oncology Frontiers 2017

Learn More

"Current Challenges for Oncolytic Viruses." Dr. Andres Gutierrez, WIC, May 2017

Learn More

"REOLYSIN® and Immune Checkpoint Inhibitors: Rationale for Combination Therapy." Dr. Giovanni Selvaggi

Learn More

"Clinical Virotherapy and Immune Modulation - Bench to Bedside and Back Again." Dr. Alan Melcher

Learn More

Publications

MOA – Tumor Lysis

"Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors." Villalona-Calero, M.A., et al., Cancer, 2016. 122(6): p. 875-83

Learn More

"The combination of intravenous REOLYSIN® and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer." Mahalingam et al, BMC Cancer (2015) 15:513

Learn More

"REOLYSIN® is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer." Carew, J.S., et al, Cell Death Dis, 2013. 4: p. e728

Learn More

"Intravenous administration of REOLYSIN®, a live replication competent RNA virus is safe in patients with advanced solid tumors." Gollamudi, R., et al, Invest New Drugs, 2010. 28(5): p. 641-9

Learn More

"Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells." Sei, S., et al, Mol Cancer, 2009. 8: p. 47

Learn More

"Oncolytic viral therapy for human pancreatic cancer cells by reovirus." Etoh, T., et al, Clin Cancer Res, 2003. 9(3): p. 1218-23

Learn More

"Reovirus oncolysis of human breast cancer." Norman, K.L., et al, Hum Gene Ther, 2002. 13(5): p. 641-52

Learn More
MOA – Immunity

"Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer."Adel Samson, BMJ Hepatology, 2016

Learn More

"Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma." Anne M Noonan, Molecular Therapy vol. 24 no. 6 jun. 2016 1151

Learn More

"Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses." Rajani, K., et al, Mol Ther, 2016. 24(1): p. 166-74

Learn More

"Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo." El-Sherbiny, Y.M., et al, Clin Exp Immunol, 2015. 180(1): p. 98-107

Learn More

"Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells." Adair, R.A., et al, Int J Cancer, 2013. 132(10): p. 2327-38

Learn More

"Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients." Adair, R.A., et al, Sci Transl Med, 2012. 4(138): p. 138ra77

Learn More

"Oncolytic virus-initiated protective immunity against prostate cancer." Gujar, S.A., et al, Mol Ther, 2011. 19(4): p. 797-804

Learn More

"Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappaB mediated and supports innate and adaptive anti-tumor immune priming." Steele, L., et al, Mol Cancer, 2011. 10: p. 20

Learn More

"Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity." Gujar, S.A., et al, Mol Cancer Ther, 2010. 9(11): p. 2924-33

Learn More

"Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication." Prestwich, R.J., et al, Clin Cancer Res, 2009. 15(13): p. 4374-81

Learn More

"Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity." Errington, F., et al, The Journal of Immunology, 2008. 180(9): p. 6018-6026

Learn More

"Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial." White, C.L., et al, Gene Ther, 2008. 15(12): p. 911-20

Learn More